Fri, 16/02/2018
Muenster scientists present their latest research
Muenster.  The Scientific Retreat of the SFB CRC-TR 128 will be held on the 9th and 10th of March 2018. PhD students and young postdocs from all labs of the Department of Neurology and Insititute for Translational Neurology in Münster will give short oral presentations summarizing their main ongoing projects. Sessions will be introduced by […]...more
Fri, 16/02/2018
Ion channels in autoimmune neurodegeneration
Muenster. Autoaggressive T Lymphocytes that have to cross the activated blood brain barrier (BBB) play an important role in the pathogenesis of MS. Prof. Sven Meuth, principal investigator in the DFG-funded cluster of excellence “Cells in Motion” and the CRC 128 “Multiple Sclerosis” focusses on the potassium channel TREK-1. It analyses the molecular pathways through […]...more
Fri, 16/02/2018
Introduction into Histopathology of MS
Muenster, The CRC-128 „Multiple Sclerosis“ offers an histopathology course for its members. The two-day seminar is open for nine selected participants who will get the chance to learn neuropathology techniques and join a microscopy session. Where?: Institute of Neuropathology, Pottkamp 2, 48149 Muenster When?: April 26-27, 2018 flyer histopathology muenster 2018  ...more

Wed, 23/11/2016 | Featured publication: Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier

Münster – The enzymes gelatinase A/matrix metalloproteinase-2 (MMP-2) and gelatinase B/MMP-9 are essential for induction of neuroinflammatory symptoms in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). In the absence of these enzymes, the disease does not develop. SFB128 scientists of Prof. Dr. Lydia Sorokin’s group, therefore, investigated the cellular sources and relative contributions of MMP-2 and MMP-9 to disease at early stages of EAE induction. They demonstrated that MMP-9 from an immune cell source is required in EAE for initial infiltration of leukocytes into the central nervous system and that MMP-9 activity is a reliable marker of leukocyte penetration of the blood-brain barrier.
The neuroscientists then developed a molecular imaging method to visualize MMP activity in the brain using fluorescent- and radioactive-labeled MMP inhibitors (MMPis).
By using radioactive MMP ligand in EAE animals the Muenster neuroscientists produced positron emission tomography (PET) images of MMP activity in patients with MS.
In contrast to traditional T1-gadolinium contrast-enhanced MRI, MMPi-PET enabled tracking of MMP activity as a unique feature of early lesions and ongoing leukocyte infiltration.
MMPi-PET therefore allows monitoring of the early steps of MS development and provides sensitive, noninvasive means of following lesion formation and resolution in murine EAE and human MS, the neuroscientists conclude. Their work was part of the SFB projects B03 and Z02.